ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Biotechnology

China's Sinopharm doubles output capacity for 2020 vaccine launch

Drugmaker's two plants can produce 200m doses as candidate moves through trials

Eighteen potential vaccines are in clinical trials, with seven being developed by Chinese pharmaceutical companies.   © Reuters

DALIAN, China -- Chinese drugmaker Sinopharm has completed construction of a plant in Wuhan for mass production of a coronavirus vaccine candidate now under development, doubling its capacity to more than 200 million doses a year 

The state-backed company, known formally as China National Pharmaceutical Group, will be able to make 100 million doses a year at the site. The investment amount has not been disclosed. After the groundbreaking in March, construction took place quickly with support from the local government.

Sinopharm, which is developing the vaccine candidate at group laboratories in Wuhan and Beijing, also set up a factory with production capacity of 120 million doses in Beijing in April. 

The Wuhan lab announced on June 16 that all subjects of its phase two clinical trial produced antibodies that neutralize the virus. Phase three of the trial will be conducted in the United Arab Emirates. The vaccine could reach the market at the end of this year.

Eighteen potential vaccines were in clinical trials globally as of Friday, with seven being developed by Chinese companies, according to the World Health Orgnization. Sinovac Biotech is building a plant in Beijing to gain the capacity for making 100 million doses a year.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media